Publications from OUS - Immunotherapy against solid cancers (Kyte)

71 publications found

Publications 2024

1. Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
   Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
   Mol Oncol (in press)
   DOI 10.1002/1878-0261.13675, PubMed 38978352
2. Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
   Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
   J Immunother Cancer, 12 (1)
   DOI 10.1136/jitc-2023-007990, PubMed 38242720
3. Chauhan SK, Dunn C, Andresen NK, Røssevold AH, Skorstad G, Sike A, Gilje B, Raj SX, Huse K, Naume B, Kyte JA (2024)
   Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
   NPJ Breast Cancer, 10 (1), 30
   DOI 10.1038/s41523-024-00638-2, PubMed 38653982
4. Jin Y, Dunn C, Persiconi I, Sike A, Skorstad G, Beck C, Kyte JA (2024)
   Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers
   Int J Mol Sci, 25 (1)
   DOI 10.3390/ijms25010586, PubMed 38203757
5. Jin Y, Dunn C, Persiconi I, Sike A, Skorstad G, Beck C, Kyte JA (2024)
   Correction: Jin et al. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. Int. J. Mol. Sci. 2024, 25, 586
   Int J Mol Sci, 25 (18)
   DOI 10.3390/ijms251810024, PubMed 39337718

Publications 2023

1. Beck C, Casey NP, Persiconi I, Moharrami NN, Sike A, Jin Y, Kyte JA (2023)
   Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy
   Biomedicines, 11 (2)
   DOI 10.3390/biomedicines11020459, PubMed 36830995
2. Chauhan SK, Bartolomé Casado R, Landsverk OJB, Johannessen H, Phung D, Nilsen HR, Sætre F, Jahnsen J, Horneland R, Yaqub S, Aandahl EM, Lundin KEA, Bækkevold ES, Jahnsen FL (2023)
   Human small intestine contains 2 functionally distinct regulatory T-cell subsets
   J Allergy Clin Immunol, 152 (1), 278-289.e6
   DOI 10.1016/j.jaci.2023.02.030, PubMed 36893861
3. Rim S, Sakkestad ST, Zhou F, Gullaksen SE, Skavland J, Chauhan SK, Steinsland H, Hanevik K (2023)
   Dynamics of circulating lymphocytes responding to human experimental enterotoxigenic Escherichia coli infection
   Eur J Immunol, 53 (8), e2250254
   DOI 10.1002/eji.202250254, PubMed 37102399

Publications 2022

1. Dorraji E, Borgen E, Segura-Peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA (2022)
   Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
   Cancers (Basel), 14 (19)
   DOI 10.3390/cancers14194859, PubMed 36230782
2. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
3. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
4. Jin Y, Lorvik KB, Jin Y, Beck C, Sike A, Persiconi I, Kvaløy E, Saatcioglu F, Dunn C, Kyte JA (2022)
   Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer
   Mol Ther Oncolytics, 26, 189-206
   DOI 10.1016/j.omto.2022.06.007, PubMed 35860008
5. Kyte JA (2022)
   Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
   Cancers (Basel), 14 (3)
   DOI 10.3390/cancers14030571, PubMed 35158839
6. Meyer-Myklestad MH, Medhus AW, Lorvik KB, Seljeflot I, Hansen SH, Holm K, Stiksrud B, Trøseid M, Hov JR, Kvale D, Dyrhol-Riise AM, Kummen M, Reikvam DH (2022)
   Human Immunodeficiency Virus-Infected Immunological Nonresponders Have Colon-Restricted Gut Mucosal Immune Dysfunction
   J Infect Dis, 225 (4), 661-674
   DOI 10.1093/infdis/jiaa714, PubMed 33216130
7. Meyer-Myklestad MH, Medhus AW, Stiksrud B, Lorvik KB, Seljeflot I, Hansen SH, Holm K, Hov JR, Kvale D, Dyrhol-Riise AM, Kummen M, Trøseid M, Reikvam DH (2022)
   Probiotics to HIV-Infected Immunological Nonresponders: Altered Mucosal Immunity and Microbial Diversity Restricted to Ileum
   J Acquir Immune Defic Syndr, 89 (1), 77-86
   DOI 10.1097/QAI.0000000000002817, PubMed 34878437
8. Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
   Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
   Nat Med, 28 (12), 2573-2583
   DOI 10.1038/s41591-022-02126-1, PubMed 36482103
9. Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
   Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
   ESMO Open, 7 (5), 100588
   DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Publications 2021

1. Lorvik KB, Meyer-Myklestad MH, Kushekar K, Handeland C, Medhus AW, Lund-Iversen M, Stiksrud B, Kvale D, Dyrhol-Riise AM, Taskén K, Reikvam DH (2021)
   Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4⁺ T Cells in HIV-Infected Immunological Non-Responders
   Front Immunol, 12, 744155
   DOI 10.3389/fimmu.2021.744155, PubMed 34691047

Publications 2020

1. Bartolomé-Casado R, Landsverk OJB, Chauhan SK, Sætre F, Hagen KT, Yaqub S, Øyen O, Horneland R, Aandahl EM, Aabakken L, Bækkevold ES, Jahnsen FL (2020)
   CD4⁺ T cells persist for years in the human small intestine and display a T_H1 cytokine profile
   Mucosal Immunol, 14 (2), 402-410
   DOI 10.1038/s41385-020-0315-5, PubMed 32572129
2. Casey NP, Kyte JA, Fujiwara H (2020)
   Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency
   Methods Mol Biol, 2115, 327-349
   DOI 10.1007/978-1-0716-0290-4_18, PubMed 32006409
3. Kuttner S, Wickstrøm KK, Kalda G, Dorraji SE, Martin-Armas M, Oteiza A, Jenssen R, Fenton K, Sundset R, Axelsson J (2020)
   Machine learning derived input-function in a dynamic ¹⁸F-FDG PET study of mice
   Biomed Phys Eng Express, 6 (1), 015020
   DOI 10.1088/2057-1976/ab6496, PubMed 33438608
4. Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
   ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
   J Transl Med, 18 (1), 269
   DOI 10.1186/s12967-020-02421-w, PubMed 32620163
5. Kyte JA, Røssevold A, Falk RS, Naume B (2020)
   ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
   J Transl Med, 18 (1), 252
   DOI 10.1186/s12967-020-02424-7, PubMed 32576225

Publications 2019

1. Bartolomé-Casado R, Landsverk OJB, Chauhan SK, Richter L, Phung D, Greiff V, Risnes LF, Yao Y, Neumann RS, Yaqub S, Øyen O, Horneland R, Aandahl EM, Paulsen V, Sollid LM, Qiao SW, Baekkevold ES, Jahnsen FL (2019)
   Resident memory CD8 T cells persist for years in human small intestine
   J Exp Med, 216 (10), 2412-2426
   DOI 10.1084/jem.20190414, PubMed 31337737
2. Kyte JA, Fåne A, Pule M, Gaudernack G (2019)
   Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
   Oncoimmunology, 8 (4), e1565236
   DOI 10.1080/2162402X.2019.1565236, PubMed 30906659
3. Stiksrud B, Aass HCD, Lorvik KB, Ueland T, Trøseid M, Dyrhol-Riise AM (2019)
   Activated dendritic cells and monocytes in HIV immunological nonresponders: HIV-induced interferon-inducible protein-10 correlates with low future CD4+ recovery
   AIDS, 33 (7), 1117-1129
   DOI 10.1097/QAD.0000000000002173, PubMed 30789356

Publications 2017

1. Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
   T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
   Oncoimmunology, 6 (4), e1302631
   DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Publications 2016

1. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
   Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
   Clin Transl Immunology, 5 (11), e109
   DOI 10.1038/cti.2016.65, PubMed 27990285
2. Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
   T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
   Oncoimmunology, 5 (12), e1249090
   DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
3. Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
   Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
   Oncoimmunology, 5 (11), e1232237
   DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Publications 2012

1. Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012)
   Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
   Oncoimmunology, 1 (5), 670-686
   DOI 10.4161/onci.20426, PubMed 22934259

Publications 2011

1. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
   Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
   Clin Cancer Res, 17 (21), 6847-57
   DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169
2. Corthay A, Lorvik KB, Bogen B (2011)
   Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer
   Scand J Immunol, 73 (6), 527-30
   DOI 10.1111/j.1365-3083.2011.02558.x, PubMed 21388431
3. Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G (2011)
   Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
   Cancer Immunol Immunother, 60 (11), 1553-64
   DOI 10.1007/s00262-011-1061-z, PubMed 21681371
4. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
   Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
   Clin Cancer Res, 17 (13), 4568-80
   DOI 10.1158/1078-0432.CCR-11-0184, PubMed 21586625

Publications 2010

1. Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM (2010)
   Transiently redirected T cells for adoptive transfer
   Cytotherapy, 13 (5), 629-40
   DOI 10.3109/14653249.2010.542461, PubMed 21174490
2. Kyte JA (2010)
   [We know more than we can understand]
   Tidsskr Nor Laegeforen, 130 (22), 2217
   DOI 10.4045/tidsskr.10.1000, PubMed 21109831
3. Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK (2010)
   Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection
   PLoS Pathog, 6 (12), e1001227
   DOI 10.1371/journal.ppat.1001227, PubMed 21187913

Publications 2009

1. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B (2009)
   Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells
   Cancer Res, 69 (14), 5901-7
   DOI 10.1158/0008-5472.CAN-08-4816, PubMed 19567679
2. Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G (2009)
   Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
   Cancer Immunol Immunother, 58 (10), 1609-26
   DOI 10.1007/s00262-009-0670-2, PubMed 19221745

Publications 2008

1. Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, Alexander G, Finney H, Lawson A, Plunkett FJ, Bertoletti A, Akbar AN, Maini MK (2008)
   Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
   J Exp Med, 205 (9), 2111-24
   DOI 10.1084/jem.20072076, PubMed 18695005
2. Døsen-Dahl G, Munthe E, Nygren MK, Stubberud H, Hystad ME, Rian E (2008)
   Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape
   Int J Cancer, 123 (12), 2759-66
   DOI 10.1002/ijc.23833, PubMed 18798273
3. Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, Peppa D, Gilson RJ, Gehring A, Bertoletti A, Maini MK (2008)
   Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection
   J Clin Invest, 118 (5), 1835-45
   DOI 10.1172/JCI33402, PubMed 18398508
4. Nygren MK, Døsen-Dahl G, Stubberud H, Wälchli S, Munthe E, Rian E (2008)
   beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells
   Exp Hematol, 37 (2), 225-33
   DOI 10.1016/j.exphem.2008.10.007, PubMed 19101069

Publications 2007

1. Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB (2007)
   Characterization of early stages of human B cell development by gene expression profiling
   J Immunol, 179 (6), 3662-71
   DOI 10.4049/jimmunol.179.6.3662, PubMed 17785802

Publications 2006

1. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006)
   Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
   Cancer Immunol Immunother, 55 (12), 1553-64
   DOI 10.1007/s00262-006-0145-7, PubMed 16491401
2. Døsen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, Rian E (2006)
   Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis
   BMC Immunol, 7, 13
   DOI 10.1186/1471-2172-7-13, PubMed 16808837
3. Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E (2006)
   BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
   Exp Hematol, 34 (1), 72-81
   DOI 10.1016/j.exphem.2005.09.010, PubMed 16413393
4. Kyte JA, Gaudernack G (2006)
   Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
   Cancer Immunol Immunother, 55 (11), 1432-42
   DOI 10.1007/s00262-006-0161-7, PubMed 16612595
5. Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2006)
   T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
   Cancer Immunol Immunother, 56 (5), 659-75
   DOI 10.1007/s00262-006-0222-y, PubMed 16947019
6. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
   Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
   Cancer Gene Ther, 13 (10), 905-18
   DOI 10.1038/sj.cgt.7700961, PubMed 16710345
7. Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, Rian E (2006)
   Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines
   Br J Haematol, 136 (3), 400-13
   DOI 10.1111/j.1365-2141.2006.06442.x, PubMed 17156404

Publications 2005

1. Hegde NR, Dunn C, Lewinsohn DM, Jarvis MA, Nelson JA, Johnson DC (2005)
   Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL
   J Exp Med, 202 (8), 1109-19
   DOI 10.1084/jem.20050162, PubMed 16216889
2. Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G (2005)
   Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
   Cancer Gene Ther, 12 (6), 579-91
   DOI 10.1038/sj.cgt.7700837, PubMed 15818380
3. Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, Reignat S, Webster G, Bertoletti A, Maini MK (2005)
   Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection
   J Infect Dis, 191 (7), 1169-79
   DOI 10.1086/428502, PubMed 15747254
4. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
   Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
   Br J Cancer, 93 (7), 749-56
   DOI 10.1038/sj.bjc.6602761, PubMed 16136047
5. Torlakovic E, Tenstad E, Funderud S, Rian E (2005)
   CD10+ stromal cells form B-lymphocyte maturation niches in the human bone marrow
   J Pathol, 205 (3), 311-7
   DOI 10.1002/path.1705, PubMed 15682430

Publications 2004

1. Reppe S, Olstad OK, Rian E, Gautvik VT, Gautvik KM, Jemtland R (2004)
   Butyrate response factor 1 is regulated by parathyroid hormone and bone morphogenetic protein-2 in osteoblastic cells
   Biochem Biophys Res Commun, 324 (1), 218-23
   DOI 10.1016/j.bbrc.2004.09.030, PubMed 15465005

Publications 2003

1. Olstad OK, Gautvik VT, Reppe S, Rian E, Jemtland R, Ohlsson C, Bruland OS, Gautvik KM (2003)
   Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning
   Anticancer Res, 23 (3B), 2201-16
   PubMed 12894494
2. Wabakken T, Rian E, Kveine M, Aasheim HC (2003)
   The human solute carrier SLC41A1 belongs to a novel eukaryotic subfamily with homology to prokaryotic MgtE Mg2+ transporters
   Biochem Biophys Res Commun, 306 (3), 718-24
   DOI 10.1016/s0006-291x(03)01030-1, PubMed 12810078

Publications 2002

1. Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, Johnson DC (2002)
   Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation
   J Virol, 76 (21), 10929-41
   DOI 10.1128/jvi.76.21.10929-10941.2002, PubMed 12368336
2. Kveine M, Tenstad E, Døsen G, Funderud S, Rian E (2002)
   Characterization of the novel human transmembrane protein 9 (TMEM9) that localizes to lysosomes and late endosomes
   Biochem Biophys Res Commun, 297 (4), 912-7
   DOI 10.1016/s0006-291x(02)02228-3, PubMed 12359240
3. Sriram V, Cho S, Li P, O'Donnell PW, Dunn C, Hayakawa K, Blum JS, Brutkiewicz RR (2002)
   Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells
   Proc Natl Acad Sci U S A, 99 (12), 8197-202
   DOI 10.1073/pnas.122636199, PubMed 12060764

Publications 2001

1. Rian E, Wabakken T, Hauge H, Aasheim HC (2001)
   A signal sequence trap based on cell enrichment using anti-CD19 antibody coated magnetic beads
   Scand J Immunol, 54 (3), 280-4
   DOI 10.1046/j.1365-3083.2001.00925.x, PubMed 11555391

Publications 2000

1. Munthe E, Rian E, Holien T, Rasmussen A, Levy FO, Aasheim H (2000)
   Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6
   FEBS Lett, 466 (1), 169-74
   DOI 10.1016/s0014-5793(99)01793-7, PubMed 10648835
2. Reppe S, Rian E, Jemtland R, Olstad OK, Gautvik VT, Gautvik KM (2000)
   Sox-4 messenger RNA is expressed in the embryonic growth plate and regulated via the parathyroid hormone/parathyroid hormone-related protein receptor in osteoblast-like cells
   J Bone Miner Res, 15 (12), 2402-12
   DOI 10.1359/jbmr.2000.15.12.2402, PubMed 11127205

Publications 1999

1. Jemtland R, Rian E, Olstad OK, Haug E, Bruland OS, Bucht E, Gautvik KM (1999)
   Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein
   J Bone Miner Res, 14 (6), 904-14
   DOI 10.1359/jbmr.1999.14.6.904, PubMed 10352098
2. Matre V, Høvring PI, Orstavik S, Frengen E, Rian E, Velickovic Z, Murray-McIntosh RP, Gautvik KM (1999)
   Structural and functional organization of the gene encoding the human thyrotropin-releasing hormone receptor
   J Neurochem, 72 (1), 40-50
   DOI 10.1046/j.1471-4159.1999.0720040.x, PubMed 9886052

Publications 1995

1. Bucht E, Rong H, Bremme K, Granberg B, Rian E, Tørring O (1995)
   Midmolecular parathyroid hormone-related peptide in serum during pregnancy, lactation and in umbilical cord blood
   Eur J Endocrinol, 132 (4), 438-43
   DOI 10.1530/eje.0.1320438, PubMed 7711881

Publications 1993

1. GORDELADZE JO, JABLONSKI G, PAULSSEN RH, PAULSSEN EJ, MORTENSEN BM, GAUTVIK KM, HAUG E, RIAN E, JEMTLAND R, FRIEDMAN E, BRULAND OS (1993)
   G-PROTEIN COUPLED SIGNALING IN OSTEOSARCOMA CELL-LINES
   FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES, 297-302

Publications 1991

1. Jemtland R, Rian E, Gautvik KM (1991)
   [Malignant humoral hypercalcemia and the parathyroid hormone related protein]
   Tidsskr Nor Laegeforen, 111 (14), 1738-42
   PubMed 2063384